Top Articles
#1 in Business Subscribe Email Print

You are here: Home > News and Society > Economics > U.S. Inflation in Decline?

Tags

  • product
  • noted
  • consumer
  • developing combination
  • developing combination
  • annual growth

  • Links

  • Managing a 21st Century Organisation
  • How You Can Get a California Medical Insurance Quote
  • Health Administration Online Schools
  • Top Articles - U.S. Inflation in Decline?

    U.S. inflation pressures have moderated in recent months. This is a critical development regarding the Federal Reserve's ability to possibly trim its key short
    According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
    -term interest rate later this year.

    We still subscribe to the view that the next Fed move will be to reduce its federal funds rate from 5.25% to 5.00% late in
    ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

    Examples of combination products may in
    the year, with a reasonable chance for a second 0.25% cut in 2008's first quarter. The rate has been stuck at 5.25% for the past 11 months.

    Trust me...I recog
    lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

    ize a statement about inflation moderation flies in the face of what you and I have paid at the gas pump and in the grocery store in recent weeks. However, the
    here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
    Fed's most critical inflation measures have been more financial market friendly in recent weeks.

    The "Core"

    The Fed focuses much more on 12-month chan
    d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

    Combination pro
    es in inflation than on data of one- or two- or three-month periods. The Fed also focuses more on the "core" rate of inflation, which excludes volatile food an
    ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
    energy costs. However, another economist noted recently that the decline in the core rate of inflation was good news "only if you don't use energy or eat food
    easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
    ."

    ...touche'

    Whether right or wrong, the Fed's inflation attention is focused on the core personal consumption expenditures index (core PCE) and the core con
    nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
    umer price index (core CPI). Fed officials actually view the PCE inflation data as better consumer inflation data than the Consumer Price Index.

    The "Targe
    and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
    "

    Current Federal Reserve Chair Ben Bernanke has spoken frequently in the past about his support of inflation targeting, i.e. establishing an official infl
    ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
    tion target range within which the Fed tries to keep core inflation. Financial markets see this as an annual target range of 1.0%-2.0%. Such inflation targeti
    ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

    Following aspects would a
    ng is commonplace in Europe, where the European Central Bank is firmly committed to the same 1.0%-2.0% range.

    While Fed Chair Bernanke has not formally adopted
    dd to the challenges in developing combination products:

    Which markets to tap where the combination products can do fairly well?
    Which combination prod
    inflation targeting at the Fed, financial markets nevertheless hold his feet to the fire as if he had. In contrast, former Fed Chair Alan Greenspan did not fav
    cts are meaningful and rational?
    Which therapeutic categories to select?
    Which Combinations can address unmet needs of the patients?
    Do combin
    r inflation targeting, but preferred to largely determine monetary policy by the seat of his pants.

    As noted, the two 12-month (known as year-over-year) core i
    tions increase the patient compliance?
    What would be the developing cost?
    How to tackle the risks encountered during combination product developmen
    nflation measures have been more favorable in recent months. The core PCE's most recent 12-month rise was down to 2.1%, within striking distance of the unoffic
    t?

    As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
    al range. In contrast, this inflation measure moved toward 3.0% over the prior 12 months. The core CPI has also behaved better, with the most recent 12-month
    ping new procedures for reviewing their safety, efficacy and quality.

    Professional from academic institutions, pharmaceutical industries, health care indust
    ise down to 2.3%, versus more worrisome core inflation increases over the past 12-15 months.

    Downshift

    The American economy has slowed over the past ye
    y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
    ar, no question. The 2.1% real (inflation adjusted) annual growth pace of the past 12 months is down more than 40% versus the healthy 3.7% real annual growth p
    .

    As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
    ce of the prior 12 months.

    Such sluggishness is comparable to a car slowing from 55mph to a 31mph pace. Recent economic slowing should help minimize inflation
    elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

    Companies that provide selfless information through particip
    pressures further in coming quarters. We expect these pressures to remain under control even as we see the economy picking up speed over the next four quarters


    tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

    HTTP = HTML link (for blogs, profiles,phorums):
    <a href="http://www.toparticles.org.ua/article/189419/toparticles-US-Inflation-in-Decline.html">U.S. Inflation in Decline?</a>

    BB link (for phorums):
    [url=http://www.toparticles.org.ua/article/189419/toparticles-US-Inflation-in-Decline.html]U.S. Inflation in Decline?[/url]

    Related Articles:

    Branding Your Own Beauty Care Line? Get Your Artwork Straight

    How to Become a Bounty Hunter in 9 Easy Steps

    Does Your Resume Sell You?

    Bookmark it: del.icio.us digg.com reddit.com netvouz.com google.com yahoo.com technorati.com furl.net bloglines.com socialdust.com ma.gnolia.com newsvine.com slashdot.org simpy.com shadows.com blinklist.com